Adoptive cell therapy: Past, present and future

Jonathan E. Cohen; Sharon Merims; Stephen Frank; Roni Engelstein; Tamar Peretz; Michal Lotem

doi:10.2217/imt-2016-0112

Adoptive cell therapy: Past, present and future

Jonathan E. Cohen^*, Sharon Merims, Stephen Frank, Roni Engelstein, Tamar Peretz, Michal Lotem

^*Corresponding author for this work

Hadassah University Medical Centre

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of ACT and treatment protocols, focusing on unresolved dilemmas regarding this treatment while providing evidence for its effectiveness in refractory patients. Future directions of ACT are discussed, in particular with regard to genetic engineering of autologous cells, and the role of ACT in the era of checkpoint inhibitors is addressed.

Original language	English
Pages (from-to)	183-196
Number of pages	14
Journal	Immunotherapy
Volume	9
Issue number	2
DOIs	https://doi.org/10.2217/imt-2016-0112
State	Published - Jan 2017
Externally published	Yes

Funding

Funders	Funder number
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Israel Science Foundation	2303/16

Keywords

adoptive cell therapy
cancer immunotherapy
tumor-infiltrating lymphocytes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/imt-2016-0112

Cite this

@article{c975be684f4d49eebf5d3c77af26d349,

title = "Adoptive cell therapy: Past, present and future",

abstract = "The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of ACT and treatment protocols, focusing on unresolved dilemmas regarding this treatment while providing evidence for its effectiveness in refractory patients. Future directions of ACT are discussed, in particular with regard to genetic engineering of autologous cells, and the role of ACT in the era of checkpoint inhibitors is addressed.",

keywords = "adoptive cell therapy, cancer immunotherapy, tumor-infiltrating lymphocytes",

author = "Cohen, {Jonathan E.} and Sharon Merims and Stephen Frank and Roni Engelstein and Tamar Peretz and Michal Lotem",

note = "Publisher Copyright: {\textcopyright} 2017 Future Medicine Ltd.",

year = "2017",

month = jan,

doi = "10.2217/imt-2016-0112",

language = "אנגלית",

volume = "9",

pages = "183--196",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "2",

}

TY - JOUR

T1 - Adoptive cell therapy

T2 - Past, present and future

AU - Cohen, Jonathan E.

AU - Merims, Sharon

AU - Frank, Stephen

AU - Engelstein, Roni

AU - Peretz, Tamar

AU - Lotem, Michal

PY - 2017/1

Y1 - 2017/1

N2 - The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of ACT and treatment protocols, focusing on unresolved dilemmas regarding this treatment while providing evidence for its effectiveness in refractory patients. Future directions of ACT are discussed, in particular with regard to genetic engineering of autologous cells, and the role of ACT in the era of checkpoint inhibitors is addressed.

AB - The immune system is a potent inhibitor of tumor growth with curative potential, constituting in many eyes the future of antineoplastic therapy. Adoptive cell therapy (ACT) is a form of immunotherapy in which autologous cancer-cognate lymphocytes are expanded and modified ex vivo and re-infused to combat the tumor. This review follows the evolvement of ACT and treatment protocols, focusing on unresolved dilemmas regarding this treatment while providing evidence for its effectiveness in refractory patients. Future directions of ACT are discussed, in particular with regard to genetic engineering of autologous cells, and the role of ACT in the era of checkpoint inhibitors is addressed.

KW - adoptive cell therapy

KW - cancer immunotherapy

KW - tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85011019285&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0112

DO - 10.2217/imt-2016-0112

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

AN - SCOPUS:85011019285

SN - 1750-743X

VL - 9

SP - 183

EP - 196

JO - Immunotherapy

JF - Immunotherapy

IS - 2

ER -

Adoptive cell therapy: Past, present and future

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this